US court clears way for launch of Allegra D24 by Dr Reddy’s

01 Feb 2011 Evaluate

Dr Reddy’s Laboratories (DRL) has secured regulatory approval for launch of its generic anti-histamine Allegra D24 in the US. The company, which has had to wait for more than six months to overcome the legal hurdles, is gearing up to launch the drug in both over the counter and prescription markets.

The market for Allegra D24 is estimated at $150-180 million. DRL had received US FDA nod for launching fexofenadine hydrochloride/ pseudoephedrine hydrochloride (Allegra D24) in March 2010. However, the drug’s innovator, Sanofi Aventis, blocked DRL’s plan to launch the drug by seeking an injunction in a US court in June 2010. By the time the US court had granted the injunction, DRL’s product was still not in the market.

Dr. Reddys Lab Share Price

1342.45 16.45 (1.24%)
20-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.50
Dr. Reddys Lab 1342.45
Cipla 1472.45
Lupin 2147.55
Zydus Lifesciences 973.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.